Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmacyclics, a developmental stage biopharmaceutical company, has appointed a new management team and a new board member. Robert Duggan, chairman of the board, has been appointed CEO of the company after acting as interim CEO for the past five months.
Subscribe to our email newsletter
Mr Duggan served as chairman of the board of directors of Computer Motion, a computerized surgical systems company, from 1990 to 2003 and CEO from 1997. Computer Motion was acquired by Intuitive Surgical in 2003. Mr Duggan currently serves as a director of Intuitive Surgical.
The company has appointed Glenn Rice as the new president and COO. Dr Rice has over 25 years of oncology drug development experience in the biopharmaceutical industry including research, preclinical and clinical trials as well as extensive experience in licensing, partnerships and mergers and acquisitions.
The company also appointed Rainer Erdtmann to head the finance department who will oversee all financial matters for the company. Jason Adelman has been appointed as a new board member and member of the audit committee for Pharmacyclics. Mr Adelman is the founder and senior managing director of Burnham Hill Partners, an investment and merchant banking firm.